Cadrenal Therapeutics (NASDAQ:CVKD) CFO Sells $21,000.00 in Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CFO Matthew Szot sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $14.00, for a total transaction of $21,000.00. Following the completion of the sale, the chief financial officer owned 29,833 shares of the company’s stock, valued at approximately $417,662. This trade represents a 4.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Cadrenal Therapeutics Price Performance

Shares of Cadrenal Therapeutics stock opened at $14.03 on Friday. The stock has a market capitalization of $28.76 million, a P/E ratio of -1.58 and a beta of 0.95. Cadrenal Therapeutics, Inc. has a 12 month low of $8.74 and a 12 month high of $22.90. The business has a 50 day simple moving average of $12.34 and a two-hundred day simple moving average of $14.10.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.27). As a group, research analysts anticipate that Cadrenal Therapeutics, Inc. will post -7.59 EPS for the current fiscal year.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.